Protocol I6T-MC-AMBI Study AMBI / LUCENT-ACT (Active Comparator Trial) is a Phase 3, randomized double blind treatthrough. Eli Lilly and Company (Eli Lilly) is developing an anti-IL-23 antibody for the treatment of ulcerativecolitis (UC). The clinical development program is designed to evaluate the safety and efficacy of mirikizumab in patients with moderately to severely active UC. LUCENT-ACT. Lilly, Principle Investigator - Faz 3